Report Thumbnail
Product Code LP0912611481W3F
Published Date 2024/3/1
English102 PagesGlobal

Global Bleeding Disorders Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0912611481W3F◆The Mar 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/3/1
English 102 PagesGlobal

Global Bleeding Disorders Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

According to our LPI (LP Information) latest study, the global Bleeding Disorders market size was valued at US$ 10580 million in 2023. With growing demand in downstream market, the Bleeding Disorders is forecast to a readjusted size of US$ 16590 million by 2030 with a CAGR of 6.6% during review period.
The research report highlights the growth potential of the global Bleeding Disorders market. Bleeding Disorders are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Bleeding Disorders. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Bleeding Disorders market.
The bleeding disorder is a condition in which there is a problem associated with the normal blood clotting process in the body, which gets affected. Hence, therapies to stop bleeding are on high demand.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Key Features:
The report on Bleeding Disorders market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Bleeding Disorders market. It may include historical data, market segmentation by Type (e.g., Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Bleeding Disorders market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Bleeding Disorders market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Bleeding Disorders industry. This include advancements in Bleeding Disorders technology, Bleeding Disorders new entrants, Bleeding Disorders new investment, and other innovations that are shaping the future of Bleeding Disorders.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Bleeding Disorders market. It includes factors influencing customer ' purchasing decisions, preferences for Bleeding Disorders product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Bleeding Disorders market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Bleeding Disorders market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Bleeding Disorders market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Bleeding Disorders industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Bleeding Disorders market.
Market Segmentation:
Bleeding Disorders market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Plasma-derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytics
Fibrin Sealants
Others
Segmentation by application
Hemophilia A
Hemophilia B
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Bayer
Baxter International
Alnylam Pharmaceuticals
Pfizer
Xenetic Biosciences
Bristol-Myers Squibb Company
Sanofi
Janssen Global Services
Bioverativ
Amgen

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Bleeding Disorders Market Size 2019-2030
      • 2.1.2 Bleeding Disorders Market Size CAGR by Region 2019 VS 2023 VS 2030
    • 2.2 Bleeding Disorders Segment by Type
      • 2.2.1 Plasma-derived Coagulation Factor Concentrates
      • 2.2.2 Recombinant Coagulation Factor Concentrates
      • 2.2.3 Desmopressin
      • 2.2.4 Antifibrinolytics
      • 2.2.5 Fibrin Sealants
      • 2.2.6 Others
    • 2.3 Bleeding Disorders Market Size by Type
      • 2.3.1 Bleeding Disorders Market Size CAGR by Type (2019 VS 2023 VS 2030)
      • 2.3.2 Global Bleeding Disorders Market Size Market Share by Type (2019-2024)
    • 2.4 Bleeding Disorders Segment by Application
      • 2.4.1 Hemophilia A
      • 2.4.2 Hemophilia B
      • 2.4.3 Others
    • 2.5 Bleeding Disorders Market Size by Application
      • 2.5.1 Bleeding Disorders Market Size CAGR by Application (2019 VS 2023 VS 2030)
      • 2.5.2 Global Bleeding Disorders Market Size Market Share by Application (2019-2024)
  • 3 Bleeding Disorders Market Size by Player

    • 3.1 Bleeding Disorders Market Size Market Share by Players
      • 3.1.1 Global Bleeding Disorders Revenue by Players (2019-2024)
      • 3.1.2 Global Bleeding Disorders Revenue Market Share by Players (2019-2024)
    • 3.2 Global Bleeding Disorders Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Bleeding Disorders by Regions

    • 4.1 Bleeding Disorders Market Size by Regions (2019-2024)
    • 4.2 Americas Bleeding Disorders Market Size Growth (2019-2024)
    • 4.3 APAC Bleeding Disorders Market Size Growth (2019-2024)
    • 4.4 Europe Bleeding Disorders Market Size Growth (2019-2024)
    • 4.5 Middle East & Africa Bleeding Disorders Market Size Growth (2019-2024)
  • 5 Americas

    • 5.1 Americas Bleeding Disorders Market Size by Country (2019-2024)
    • 5.2 Americas Bleeding Disorders Market Size by Type (2019-2024)
    • 5.3 Americas Bleeding Disorders Market Size by Application (2019-2024)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Bleeding Disorders Market Size by Region (2019-2024)
    • 6.2 APAC Bleeding Disorders Market Size by Type (2019-2024)
    • 6.3 APAC Bleeding Disorders Market Size by Application (2019-2024)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Bleeding Disorders by Country (2019-2024)
    • 7.2 Europe Bleeding Disorders Market Size by Type (2019-2024)
    • 7.3 Europe Bleeding Disorders Market Size by Application (2019-2024)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Bleeding Disorders by Region (2019-2024)
    • 8.2 Middle East & Africa Bleeding Disorders Market Size by Type (2019-2024)
    • 8.3 Middle East & Africa Bleeding Disorders Market Size by Application (2019-2024)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Bleeding Disorders Market Forecast

    • 10.1 Global Bleeding Disorders Forecast by Regions (2025-2030)
      • 10.1.1 Global Bleeding Disorders Forecast by Regions (2025-2030)
      • 10.1.2 Americas Bleeding Disorders Forecast
      • 10.1.3 APAC Bleeding Disorders Forecast
      • 10.1.4 Europe Bleeding Disorders Forecast
      • 10.1.5 Middle East & Africa Bleeding Disorders Forecast
    • 10.2 Americas Bleeding Disorders Forecast by Country (2025-2030)
      • 10.2.1 United States Bleeding Disorders Market Forecast
      • 10.2.2 Canada Bleeding Disorders Market Forecast
      • 10.2.3 Mexico Bleeding Disorders Market Forecast
      • 10.2.4 Brazil Bleeding Disorders Market Forecast
    • 10.3 APAC Bleeding Disorders Forecast by Region (2025-2030)
      • 10.3.1 China Bleeding Disorders Market Forecast
      • 10.3.2 Japan Bleeding Disorders Market Forecast
      • 10.3.3 Korea Bleeding Disorders Market Forecast
      • 10.3.4 Southeast Asia Bleeding Disorders Market Forecast
      • 10.3.5 India Bleeding Disorders Market Forecast
      • 10.3.6 Australia Bleeding Disorders Market Forecast
    • 10.4 Europe Bleeding Disorders Forecast by Country (2025-2030)
      • 10.4.1 Germany Bleeding Disorders Market Forecast
      • 10.4.2 France Bleeding Disorders Market Forecast
      • 10.4.3 UK Bleeding Disorders Market Forecast
      • 10.4.4 Italy Bleeding Disorders Market Forecast
      • 10.4.5 Russia Bleeding Disorders Market Forecast
    • 10.5 Middle East & Africa Bleeding Disorders Forecast by Region (2025-2030)
      • 10.5.1 Egypt Bleeding Disorders Market Forecast
      • 10.5.2 South Africa Bleeding Disorders Market Forecast
      • 10.5.3 Israel Bleeding Disorders Market Forecast
      • 10.5.4 Turkey Bleeding Disorders Market Forecast
      • 10.5.5 GCC Countries Bleeding Disorders Market Forecast
    • 10.6 Global Bleeding Disorders Forecast by Type (2025-2030)
    • 10.7 Global Bleeding Disorders Forecast by Application (2025-2030)
  • 11 Key Players Analysis

    • 11.1 Novo Nordisk
      • 11.1.1 Novo Nordisk Company Information
      • 11.1.2 Novo Nordisk Bleeding Disorders Product Offered
      • 11.1.3 Novo Nordisk Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.1.4 Novo Nordisk Main Business Overview
      • 11.1.5 Novo Nordisk Latest Developments
    • 11.2 Bayer
      • 11.2.1 Bayer Company Information
      • 11.2.2 Bayer Bleeding Disorders Product Offered
      • 11.2.3 Bayer Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.2.4 Bayer Main Business Overview
      • 11.2.5 Bayer Latest Developments
    • 11.3 Baxter International
      • 11.3.1 Baxter International Company Information
      • 11.3.2 Baxter International Bleeding Disorders Product Offered
      • 11.3.3 Baxter International Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.3.4 Baxter International Main Business Overview
      • 11.3.5 Baxter International Latest Developments
    • 11.4 Alnylam Pharmaceuticals
      • 11.4.1 Alnylam Pharmaceuticals Company Information
      • 11.4.2 Alnylam Pharmaceuticals Bleeding Disorders Product Offered
      • 11.4.3 Alnylam Pharmaceuticals Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.4.4 Alnylam Pharmaceuticals Main Business Overview
      • 11.4.5 Alnylam Pharmaceuticals Latest Developments
    • 11.5 Pfizer
      • 11.5.1 Pfizer Company Information
      • 11.5.2 Pfizer Bleeding Disorders Product Offered
      • 11.5.3 Pfizer Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.5.4 Pfizer Main Business Overview
      • 11.5.5 Pfizer Latest Developments
    • 11.6 Xenetic Biosciences
      • 11.6.1 Xenetic Biosciences Company Information
      • 11.6.2 Xenetic Biosciences Bleeding Disorders Product Offered
      • 11.6.3 Xenetic Biosciences Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.6.4 Xenetic Biosciences Main Business Overview
      • 11.6.5 Xenetic Biosciences Latest Developments
    • 11.7 Bristol-Myers Squibb Company
      • 11.7.1 Bristol-Myers Squibb Company Company Information
      • 11.7.2 Bristol-Myers Squibb Company Bleeding Disorders Product Offered
      • 11.7.3 Bristol-Myers Squibb Company Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.7.4 Bristol-Myers Squibb Company Main Business Overview
      • 11.7.5 Bristol-Myers Squibb Company Latest Developments
    • 11.8 Sanofi
      • 11.8.1 Sanofi Company Information
      • 11.8.2 Sanofi Bleeding Disorders Product Offered
      • 11.8.3 Sanofi Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.8.4 Sanofi Main Business Overview
      • 11.8.5 Sanofi Latest Developments
    • 11.9 Janssen Global Services
      • 11.9.1 Janssen Global Services Company Information
      • 11.9.2 Janssen Global Services Bleeding Disorders Product Offered
      • 11.9.3 Janssen Global Services Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.9.4 Janssen Global Services Main Business Overview
      • 11.9.5 Janssen Global Services Latest Developments
    • 11.10 Bioverativ
      • 11.10.1 Bioverativ Company Information
      • 11.10.2 Bioverativ Bleeding Disorders Product Offered
      • 11.10.3 Bioverativ Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.10.4 Bioverativ Main Business Overview
      • 11.10.5 Bioverativ Latest Developments
    • 11.11 Amgen
      • 11.11.1 Amgen Company Information
      • 11.11.2 Amgen Bleeding Disorders Product Offered
      • 11.11.3 Amgen Bleeding Disorders Revenue, Gross Margin and Market Share (2019-2024)
      • 11.11.4 Amgen Main Business Overview
      • 11.11.5 Amgen Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.